Special Issue "Neuro-Imaging in Parkinson’s Disease"

A special issue of Tomography (ISSN 2379-139X). This special issue belongs to the section "Neuroimaging".

Deadline for manuscript submissions: closed (1 December 2021) | Viewed by 1452

Special Issue Editor

Dr. Ryan R. Walsh
E-Mail Website
Guest Editor
Muhammad Ali Parkinson Center, Barrow Neurological Institute, Phoenix, AZ 85013, USA
Interests: Parkinson’s Disease; parkinsonism; Huntington’s Disease; Lewy Body Disorders; movement disorders; neuroimaging across neurodegenerative diseases; MRI; clinical trials

Special Issue Information

Dear Colleagues,

Neuro-Imaging in Parkinson’s Disease (PD) is in a phase of rapid evolution. From molecular imaging to PET-based imaging, to multi-modal MRI, neuroimaging in PD has reached a critical mass of investigative capacity. The ability of neuroimaging to diagnose, monitor response to treatment, and predict symptom development in PD has made important strides. This has resulted not only in an improved understanding of PD itself, but also in imaging tools with utility in the clinic and in clinical research. Thus, this is a fertile and opportune time to review the past, present, and future of neuroimaging in PD, including consideration of the field through the lens of the NIH, industry, basic science, and clinical/translational science perspectives. Papers addressing these topics are invited for this Special Issue, especially those combining a high academic standard coupled with a focus on identifying the remaining challenges in the field and suggesting pathways forward.

Dr. Ryan R. Walsh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tomography is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Parkinson’s Disease
  • SPECT
  • PET
  • MRI
  • Multi-modal
  • Dopamine
  • Dopamine transporter
  • Synuclein
  • Molecular imaging
  • Clinical trial

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Practical Application of DaTQUANT with Optimal Threshold for Diagnostic Accuracy of Dopamine Transporter SPECT
Tomography 2021, 7(4), 980-989; https://doi.org/10.3390/tomography7040081 - 18 Dec 2021
Viewed by 926
Abstract
Evaluation of Parkinsonian Syndromes (PS) with Ioflupane iodine-123 dopamine transporter single photon emission computed tomography (DaT-SPECT), in conjunction with history and clinical examination, aids in diagnosis. FDA-approved, semi-quantitative software, DaTQUANTTM (GE Healthcare, Chicago, IL, USA) is available to assist in interpretation. This [...] Read more.
Evaluation of Parkinsonian Syndromes (PS) with Ioflupane iodine-123 dopamine transporter single photon emission computed tomography (DaT-SPECT), in conjunction with history and clinical examination, aids in diagnosis. FDA-approved, semi-quantitative software, DaTQUANTTM (GE Healthcare, Chicago, IL, USA) is available to assist in interpretation. This study aims to evaluate the optimal variables and thresholds of DaTQUANT to yield the optimal diagnostic accuracy. It is a retrospective review with three different patient populations. DaT-SPECT images from all three study groups were evaluated using DaTQUANTTM software, and both single and multi-variable logistic regression were used to model PS status. The optimal models were chosen via accuracy, sensitivity, and specificity, then evaluated on the other study groups. Among single variable models, the posterior putamen yielded the highest accuracy (84% to 95%), while balancing sensitivity and specificity. Multi-variable models did not substantially improve the accuracy. When the optimal single variable models for each group were used to evaluate the remaining two groups, comparable results were achieved. In typical utilization of DaT-SPECT for differentiation between nigrostriatal degenerative disease (NSDD) and non-NSDD, the posterior putamen was the single variable that yielded the highest accuracy across three different patient populations. The posterior putamen’s recommended thresholds for DaTQUANT are SBR ≤ 1.0, z-score of ≤−1.8 and percent deviation ≤ −0.34. Full article
(This article belongs to the Special Issue Neuro-Imaging in Parkinson’s Disease)
Show Figures

Figure 1

Back to TopTop